MCID: HPT022
MIFTS: 56

Hepatoblastoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 77 54 38 30 56 6 45 15 17 74
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
KEGG 38 H02302
MeSH 45 D018197
NCIt 51 C3728
SNOMED-CT 69 45024009
ICD10 34 C22.2
UMLS 74 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 54 Hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome). Treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy.

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to beckwith-wiedemann syndrome and hepatocellular carcinoma, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Wnt signaling pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and fetal liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 beckwith-wiedemann syndrome 32.1 AFP CDKN1C GPC3 H19 IGF2 TP53
2 hepatocellular carcinoma 31.5 AFP APC BIRC5 CASP3 CRNDE CTNNB1
3 familial adenomatous polyposis 31.0 APC CTNNB1 TP53
4 embryonal sarcoma 30.4 CTNNB1 GPC3 TP53
5 teratoma 30.4 AFP KRT7 TP53
6 hemihyperplasia, isolated 30.3 CDKN1C H19 IGF2
7 familial adenomatous polyposis 1 30.3 APC CTNNB1
8 adenocarcinoma 30.2 APC BIRC5 CTNNB1 H19 TP53
9 adenoma 30.1 APC CTNNB1 PLAG1 TP53
10 intrahepatic cholangiocarcinoma 29.7 AFP CTNNB1 KRT7 TP53 TUG1
11 cholangiocarcinoma 29.0 AFP CTNNB1 GPC3 H19 HGF KRT7
12 lung cancer susceptibility 3 28.2 APC BIRC5 CASP3 CTNNB1 CYCS H19
13 breast cancer 28.1 APC BIRC5 CASP3 CRNDE CTNNB1 CYCS
14 mixed hepatoblastoma 12.3
15 macrotrabecular hepatoblastoma 12.1
16 hypobetalipoproteinemia, familial, 2 11.4
17 chylomicron retention disease 11.1
18 desmoid disease, hereditary 10.5 APC CTNNB1
19 silver-russell syndrome due to an imprinting defect of 11p15 10.5 H19 IGF2
20 silver-russell syndrome due to 11p15 microduplication 10.5 H19 IGF2
21 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
22 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.5 H19 IGF2
23 hepatitis 10.4
24 intestinal benign neoplasm 10.4 APC CTNNB1 TP53
25 short-rib thoracic dysplasia 4 with or without polydactyly 10.4 CASP3 TP53
26 peutz-jeghers syndrome 10.4 APC CTNNB1 TP53
27 colorectal adenoma 10.4 APC CTNNB1 TP53
28 atypical teratoid rhabdoid tumor 10.4 CTNNB1 IGF2 TP53
29 pharynx cancer 10.4 CASP3 CTNNB1 TP53
30 embryoma 10.4 AFP GPC3 IGF2
31 testicular malignant germ cell cancer 10.4 AFP GPC3
32 nasopharyngeal disease 10.4 CASP3 CTNNB1 TP53
33 cervix disease 10.4 CASP3 CTNNB1 TP53
34 hepatitis b 10.4
35 hyperplastic polyposis syndrome 10.3 APC TP53
36 male reproductive organ cancer 10.3 CASP3 CTNNB1 TP53
37 colonic disease 10.3 CASP3 CTNNB1 TP53
38 tongue cancer 10.3 CASP3 CTNNB1 TP53
39 stomach disease 10.3 CASP3 CTNNB1 TP53
40 female reproductive system disease 10.3 CASP3 CTNNB1 TP53
41 reproductive system disease 10.3 CASP3 CTNNB1 TP53
42 chromosomal triplication 10.3
43 respiratory system cancer 10.3 CASP3 CTNNB1 TP53
44 testicular germ cell tumor 10.3 AFP GPC3 TP53
45 germ cell cancer 10.3 AFP H19 IGF2
46 intrahepatic bile duct adenoma 10.3 AFP KRT7
47 hepatic adenomas, familial 10.3 AFP APC CTNNB1 GPC3
48 uterine anomalies 10.3 AFP CASP3 CTNNB1 TP53
49 intestinal disease 10.3 CASP3 CTNNB1 TP53
50 ovarian embryonal carcinoma 10.3 AFP GPC3

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

27 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.98 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.98 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.98 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.98 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.98 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.98 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.98 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.98 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.98 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.98 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.98 AFP APC KRT7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.98 IGF2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.98 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.98 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 AFP APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.98 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.98 APC CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.98 AFP IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.98 AFP
21 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 CTNNB1 IGF2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.98 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.98 APC KRT7 CTNNB1 IGF2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.98 CTNNB1 IGF2

MGI Mouse Phenotypes related to Hepatoblastoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 APC APOA1 BIRC5 CASP3 CTNNB1 CYCS
2 cardiovascular system MP:0005385 10.24 APC APOA1 CASP3 CDO1 CTNNB1 CYCS
3 homeostasis/metabolism MP:0005376 10.15 AFP APC APOA1 BIRC5 CASP3 CDO1
4 endocrine/exocrine gland MP:0005379 10.14 AFP APC APOA1 BIRC5 CASP3 CDO1
5 embryo MP:0005380 10.09 APC BIRC5 CTNNB1 CYCS GPC3 HGF
6 craniofacial MP:0005382 10.06 APC CASP3 CDO1 CTNNB1 CYCS GPC3
7 integument MP:0010771 9.92 APC APOA1 CASP3 CTNNB1 GPC3 IGF2
8 liver/biliary system MP:0005370 9.86 AFP APC APOA1 CTNNB1 HGF IGF2
9 pigmentation MP:0001186 9.55 APC CASP3 CTNNB1 GPC3 TP53
10 renal/urinary system MP:0005367 9.5 APC CASP3 CTNNB1 GPC3 IGF2 KRT7
11 reproductive system MP:0005389 9.28 AFP APC CASP3 CDO1 CTNNB1 GPC3

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 1,Not Applicable 135968-09-1
2
Sargramostim Approved, Investigational Phase 4,Phase 1,Not Applicable 123774-72-1, 83869-56-1
3
Nicotine Approved Phase 4 54-11-5 89594 942
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Adjuvants, Immunologic Phase 4,Phase 1,Not Applicable
6
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
7
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
10
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
11
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
12
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
14
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3 61825-94-3 43805 6857599 5310940 9887054
15
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
16
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 3 284461-73-0 216239 406563
17
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
20
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 70789204 6442177
21
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
22
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
23
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
24
Histamine Approved, Investigational Phase 3 51-45-6 774
25
Cyproheptadine Approved Phase 3 129-03-3 2913
26
Doxil Approved June 1999 Phase 3,Phase 2 31703
27
Camptothecin Experimental Phase 3 7689-03-4
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Liver Extracts Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
33 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3,Phase 1
34 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
35 Protective Agents Phase 3,Phase 1,Not Applicable
36 Radiation-Protective Agents Phase 3,Phase 1
37 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
41 sodium thiosulfate Phase 3
42 Antitubercular Agents Phase 3
43 Antioxidants Phase 3
44 Chelating Agents Phase 3
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1
46 Antidotes Phase 3
47 Dermatologic Agents Phase 2, Phase 3,Phase 3
48 Keratolytic Agents Phase 2, Phase 3
49 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3
50 Podophyllotoxin Phase 2, Phase 3 518-28-5

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
2 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
4 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer Completed NCT00652132 Phase 3 cisplatin;sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Active, not recruiting NCT00980460 Phase 3 Cisplatin;Dexrazoxane;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
9 the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Not yet recruiting NCT03728543 Phase 2, Phase 3 Sugammadex
10 To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
11 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
12 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
13 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
14 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
15 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
16 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
17 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
18 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
19 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
20 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
21 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
22 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
23 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
24 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
25 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
26 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
27 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
28 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
29 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213665 Phase 2 Tazemetostat
30 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
31 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Tacrolimus
32 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 Imetelstat Sodium
33 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Completed NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
34 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
35 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
36 Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Recruiting NCT03507491 Phase 1 Gemcitabine;Nab-paclitaxel
37 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
38 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Active, not recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
39 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
40 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
41 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
42 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
43 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
44 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
45 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
46 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
47 Molecular Basis of Pediatric Liver Cancer Recruiting NCT03959800
48 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Not Applicable Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel;Anti-seizure prophylaxis;Ursodiol
49 Diagnostic Accuracy of PIVKA-II Combining With Alpha-Fetoprotein in Hepatic Tumor Not yet recruiting NCT03645655
50 Can Pre-operative Flexible 3D Models of Pulmonary Malformations Facilitate Thoracoscopic Resection Not yet recruiting NCT03913416 Not Applicable

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

# Genetic test Affiliating Genes
1 Hepatoblastoma 30

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

42
Liver, Lung, Fetal Liver, Kidney, Breast, Myeloid, Tongue

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 1481)
# Title Authors Year
1
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome. ( 30270492 )
2019
2
Hepatoblastoma and Wilms' tumour in an infant with Beckwith-Wiedemann syndrome and diazoxide resistant congenital hyperinsulinism. ( 30817313 )
2019
3
Diagnostic Performance of 2-D Shear Wave Elastography for Differentiation of Hepatoblastoma and Hepatic Hemangioma in Children under 3 Years of Age. ( 30979592 )
2019
4
Hepatoblastoma Mimicking Hemangioma in Labeled Red Blood Cell Scintigraphy. ( 30624263 )
2019
5
Hepatitis C virus nonstructural 5A protein inhibits the starvation‑induced apoptosis of hepatoblastoma cells by increasing Beclin 1 expression. ( 30896822 )
2019
6
Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. ( 30160353 )
2019
7
Results of surgical resections with positive margins for children with hepatoblastoma: Case series from a single Asian center. ( 30255649 )
2019
8
Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong. ( 30270490 )
2019
9
Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation. ( 30320362 )
2019
10
Reiterative Radiofrequency Ablation in the Management of Pediatric Patients with Hepatoblastoma Metastases to the Lung, Liver, or Bone. ( 30350173 )
2019
11
H19 suppresses the growth of hepatoblastoma cells by promoting their apoptosis via the signaling pathways of miR-675/FADD and miR-138/PTK2. ( 30367502 )
2019
12
Inhibition of autophagy enhances adenosine‑induced apoptosis in human hepatoblastoma HepG2 cells. ( 30535464 )
2019
13
Longitudinal Monitoring of Alpha-Fetoprotein by Dried Blood Spot for Hepatoblastoma Screening in Beckwith⁻Wiedemann Syndrome. ( 30646549 )
2019
14
JTC-801 inhibits the proliferation and metastasis of the Hep G2 hepatoblastoma cell line by regulating the phosphatidylinositol 3-kinase/protein kinase B signalling pathway. ( 30675258 )
2019
15
Hepatoblastoma with Precocious Puberty. ( 30686892 )
2019
16
Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. ( 30719825 )
2019
17
Contemporary management of hepatoblastoma. ( 30762666 )
2019
18
Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients. ( 30778701 )
2019
19
TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. ( 30794805 )
2019
20
β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis. ( 30794807 )
2019
21
Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastoma. ( 30803146 )
2019
22
CircHMGCS1 Promotes Hepatoblastoma Cell Proliferation by Regulating the IGF Signaling Pathway and Glutaminolysis. ( 30809316 )
2019
23
Multifocal hepatoblastoma: What is the risk of recurrent disease in the remnant liver? ( 30819543 )
2019
24
mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development. ( 30863496 )
2019
25
Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells. ( 30864675 )
2019
26
Pure fetal hepatoblastoma in a young female. ( 30881978 )
2019
27
Arctigenin induces apoptosis in human hepatoblastoma cells. ( 30891641 )
2019
28
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival. ( 30898394 )
2019
29
Congenital hepatoblastoma in a growing health economy. ( 30898949 )
2019
30
Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. ( 30909445 )
2019
31
The Role of MicroRNAs in Hepatoblastoma Tumors. ( 30909459 )
2019
32
Use of a donor iliac vein graft for reconstruction of the inferior vena cava in liver transplantation for hepatoblastoma with caval extension. ( 30946509 )
2019
33
Central Hepatectomy (Mesohepatectomy) by Double Liver Hanging Maneuver (DLHM) in a Child with Hepatoblastoma. ( 30948871 )
2019
34
PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells. ( 30969990 )
2019
35
Is it worth completely resecting hepatoblastoma at diagnosis? ( 30975628 )
2019
36
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. ( 30975630 )
2019
37
Fourier transform infrared and Raman-based biochemical profiling of different grades of pure foetal-type hepatoblastoma. ( 30993892 )
2019
38
Retrospective Analysis of Childhood Hepatoblastoma in a Single Centre in China. ( 31000431 )
2019
39
Fine-needle aspiration cytology and cell block in diagnosis and subtyping of hepatoblastoma. ( 31009172 )
2019
40
Genetic Profile and Clinical Implications of Hepatoblastoma and Neuroblastoma Coexistence in a Child. ( 31019896 )
2019
41
Robot-assisted gallbladder-preserving hepatectomy for treating S5 hepatoblastoma in a child: A case report and review of the literature. ( 31024959 )
2019
42
Erythrocytosis and fatigue fractures associated with hepatoblastoma in a 3-year-old gelding. ( 31038324 )
2019
43
Monosegmental ALPPS: a long-term survival alternative to liver transplant in PRETEXT IV hepatoblastoma. ( 31086654 )
2019
44
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children. ( 31086727 )
2019
45
Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study. ( 31089779 )
2019
46
Hepatoblastoma in a Child With Early-onset Cirrhosis. ( 29420370 )
2019
47
Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival. ( 29668545 )
2019
48
MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance. ( 29889802 )
2019
49
Prognostic Factors for Liver Transplantation in Unresectable Hepatoblastoma. ( 30086577 )
2019
50
Hepatoblastoma in an extremely low birth-weight infant with Beckwith-Wiedemann syndrome. ( 29203194 )
2018

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6 (show all 26)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
2 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh38 Chromosome 5, 112839777: 112839777
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
5 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh37 Chromosome 3, 41266124: 41266124
6 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh38 Chromosome 3, 41224633: 41224633
7 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
8 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
9 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
10 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
11 CDK4 NM_000075.3(CDK4): c.625C> T (p.Arg209Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs140644696 GRCh37 Chromosome 12, 58144446: 58144446
12 CDK4 NM_000075.3(CDK4): c.625C> T (p.Arg209Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs140644696 GRCh38 Chromosome 12, 57750663: 57750663
13 RAF1 NM_002880.3(RAF1): c.226A> G (p.Met76Val) single nucleotide variant Uncertain significance rs730880999 GRCh37 Chromosome 3, 12653543: 12653543
14 RAF1 NM_002880.3(RAF1): c.226A> G (p.Met76Val) single nucleotide variant Uncertain significance rs730880999 GRCh38 Chromosome 3, 12612044: 12612044
15 STK11 NM_000455.4(STK11): c.397G> A (p.Val133Met) single nucleotide variant Uncertain significance rs567769257 GRCh38 Chromosome 19, 1219346: 1219346
16 STK11 NM_000455.4(STK11): c.397G> A (p.Val133Met) single nucleotide variant Uncertain significance rs567769257 GRCh37 Chromosome 19, 1219345: 1219345
17 MSH6 NM_000179.2(MSH6): c.942C> G (p.Ser314Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150440246 GRCh37 Chromosome 2, 48026064: 48026064
18 MSH6 NM_000179.2(MSH6): c.942C> G (p.Ser314Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150440246 GRCh38 Chromosome 2, 47798925: 47798925
19 PTCH1 NM_000264.4(PTCH1): c.2270T> C (p.Phe757Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs547954117 GRCh37 Chromosome 9, 98229688: 98229688
20 PTCH1 NM_000264.4(PTCH1): c.2270T> C (p.Phe757Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs547954117 GRCh38 Chromosome 9, 95467406: 95467406
21 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other rs1553630102 GRCh38 Chromosome 3, 41224596: 41224607
22 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other rs1553630102 GRCh37 Chromosome 3, 41266087: 41266098
23 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh37 Chromosome 22, 28195603: 28195605
24 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh38 Chromosome 22, 27799615: 27799617
25 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other rs1553153748 GRCh37 Chromosome 1, 27106648: 27106648
26 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other rs1553153748 GRCh38 Chromosome 1, 26780157: 26780157

Copy number variations for Hepatoblastoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to KEGG:

38
# Name Kegg Source Accession
1 Wnt signaling pathway hsa04310

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 APC CASP3 CTNNB1 HGF IGF2 TP53
2
Show member pathways
12.67 BIRC5 CASP3 CYCS IGF2 TP53
3
Show member pathways
12.66 APC BIRC5 CASP3 CTNNB1 CYCS TP53
4
Show member pathways
12.62 APC CTNNB1 HGF IGF2 TP53
5
Show member pathways
12.43 APC CASP3 CTNNB1 CYCS HGF TP53
6 12.3 APC BIRC5 CTNNB1 TP53
7
Show member pathways
12.27 APC CTNNB1 GPC3 TP53
8 11.98 AFP APC BIRC5 CTNNB1
9 11.95 APC BIRC5 CASP3 CTNNB1 CYCS HGF
10 11.88 AFP APC HGF TP53
11 11.77 APC BIRC5 CASP3 CTNNB1 TP53
12 11.74 CASP3 CYCS TP53
13 11.74 CASP3 CTNNB1 GPC3 HGF IGF2 TP53
14 11.71 APC CTNNB1 IGF2 TP53
15
Show member pathways
11.68 BIRC5 CASP3 CYCS
16
Show member pathways
11.54 CASP3 CYCS TP53
17 11.43 APC CASP3 TP53
18 11.42 BIRC5 CASP3 CYCS TP53
19 11.39 BIRC5 CASP3 TP53
20 11.17 CASP3 CYCS TP53
21 11.06 APC CTNNB1 HGF

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
2 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 BIRC5 CASP3 CTNNB1 HGF TP53
2 cytokine-mediated signaling pathway GO:0019221 9.73 BIRC5 CASP3 HGF TP53
3 negative regulation of transcription, DNA-templated GO:0045892 9.72 BIRC5 CDKN1C CTNNB1 PPARA TP53
4 negative regulation of inflammatory response GO:0050728 9.65 APOA1 HGF PPARA
5 cellular protein metabolic process GO:0044267 9.46 AFP APOA1 GPC3 IGF2
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 HGF IGF2 TP53
7 anterior/posterior axis specification GO:0009948 9.4 CTNNB1 GPC3
8 striated muscle cell differentiation GO:0051146 9.37 CASP3 IGF2
9 embryonic placenta morphogenesis GO:0060669 8.96 CDKN1C IGF2
10 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.8 APC CASP3 CDKN1C

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....